PSMA Addition (Phase III)

Investigator physician: Pr Pierre OLIVIER

An International Prospective Open-label, Randomized, Phase III Study comparing ¹⁷⁷Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A prospective, open-label, international Phase III study involving 1126 patients (75 in France). These patients have hormone-sensitive metastatic prostate cancer, whose tumor expresses the PSMA antigen, have received no or minimal prior treatment, and will be randomized (1:1) to receive either standard therapy alone or standard therapy in combination with ¹⁷⁷Lu-PSMA-617.

The treatment under study: ¹⁷⁷Lu-PSMA-617
Study status: Closed Follow-up of patients
Clinical Trial number: NCT04720157
Funding: